Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Neflamapimod - EIP Pharma

Drug Profile

Neflamapimod - EIP Pharma

Alternative Names: VX-745

Latest Information Update: 15 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vertex Pharmaceuticals
  • Developer EIP Pharma; Vertex Pharmaceuticals
  • Class Anti-inflammatories; Antidementias; Nootropics; Pyridazines; Small molecules; Sulfides
  • Mechanism of Action P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease; Huntington's disease; Lewy body disease
  • Discontinued Asthma; Crohn's disease; Rheumatoid arthritis; Stroke

Most Recent Events

  • 08 Nov 2019 Safety data from the phase IIb REVERSE-SD trial for Alzheimer's disease released by EIP Pharma
  • 08 Nov 2019 Neflamapimod - EIP Pharma receives Fast Track designation for Lewy body disease [PO,Capsule] in USA
  • 31 Jul 2019 EIP Pharma completes the phase II REVERSE-SD trial in Alzheimer's disease in USA, Czech Republic, Denmark, Netherlands and United Kingdom (NCT03402659)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top